The International Cancer Proteogenomic Consortium (ICPC)

Launched in late 2016, the International Cancer Proteogenomic Consortium (ICPC) was catalysed by the initial efforts of Cancer Moonshot, US. The ICPC is a scientific organisation that provides a forum for collaboration between some of the leading international cancer and proteogenomic research centres.  The main focus of the ICPC organisation are the following:

  • To encourage international cooperation and investment amongst nations in cancer research and cancer care.
  • Bring together leading scientists for new efforts in precision medicine.
  • Collaboration within the application of proteogenomic analysis in predicting cancer treatment success and to share data and results with researchers worldwide, ultimately hastening treatment progress for patients.

All nations present at the ICPC meeting, HUPO 2017, Dublin, Ireland 

Cancer Moonshot Lund, Sweden is a member of ICPC that also includes teams in Australia, Canada, China, Germany, Japan, South Korea, Switzerland, Taiwan, United Kingdom and the United States.